Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Top Line data of 2 Phase 3 trials for Bremelanotide in female sexual dysfunction (FSD)

Source Link:: http://www.prnewswire.com/news-releases/palatin-technologies-achieves-target-patient-enrollment-in-pivotal-phase-3-studies-for-bremelanotide-for-female-sexual-dysfunction-300191004.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

PTN

50%

VRX

50%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Management Comment "We are grateful for the enthusiastic response from our clinical investigators and strong interest from patients to participate in our Phase 3 reconnect study program." Dr. Spana further stated that, "This puts us on target to release top-line data results in the third quarter of calendar year 2016."

http://www.prnewswir...

Additional Relevant Details Update on 9.12.16: "We now look forward to data verification and database lock, which we anticipate occurring in late September, with topline data announced shortly thereafter."

http://www.irdirect....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Nov 01, 2016

Occurred Source:

http://www.irdirect.net/prviewer/release/id/2174818

Related Projects

How likely is success for the Phase 3 trials of Bremelanotide in female sexual dysfunction based on the previously released studies? PTN, VRX Executed On: Sep 30, 2016 at 09:00 AM EDT
Moving past VRX's tough fall, was the Sprout / Addyi purchase a great buy or waste of money for the company? And is Palatin's drug more like the injectable "Female Viagra" everyone is looking for? VRX, PTN Executed On: Dec 11, 2015 at 02:00 PM EST

Related Keywords Addyi, Bremelanotide, Hsdd, Fsd, Female Sexual Dysfunction